Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

10x Genomics Inc

TXG
20,4156
0,6456 (3,27%)
21 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/6/202415:00PRNUS10x Genomics Begins Commercial Shipments of Xenium Prime 5K..
13/6/202422:08EDGAR2Form 8-K - Current report
06/6/202422:13EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
31/5/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:05PRNUS10x Genomics Launches 5,000-Plex Gene Panel for Xenium
24/5/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202401:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202401:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/5/202422:27EDGAR2Form 144 - Report of proposed sale of securities
22/5/202422:23EDGAR2Form 144 - Report of proposed sale of securities
22/5/202422:17EDGAR2Form 144 - Report of proposed sale of securities
02/5/202422:05PRNUS10x Genomics to Present at the BofA Securities 2024..
30/4/202422:05PRNUS10x Genomics Reports First Quarter 2024 Financial Results
10/4/202422:05PRNUS10x Genomics to Report First Quarter 2024 Financial Results..
26/3/202414:00PRNUS10x Genomics Commercially Launches Visium HD Spatial Gene..
21/3/202421:05PRNUS10x Genomics Expands Xenium Menu with Multi-Modal Cell..
13/3/202421:05PRNUS10x Genomics Begins Commercial Shipments of Chromium GEM-X..
06/3/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:40EDGAR2Form 144 - Report of proposed sale of securities
26/2/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202401:19EDGAR2Form 144 - Report of proposed sale of securities
23/2/202401:06EDGAR2Form 144 - Report of proposed sale of securities
23/2/202400:59EDGAR2Form 144 - Report of proposed sale of securities
20/2/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:05PRNUS10x Genomics to Present at the 44th Annual TD Cowen Health..
15/2/202423:33EDGAR2Form S-8 - Securities to be offered to employees in employee..
15/2/202423:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202422:05EDGAR2Form 8-K - Current report
15/2/202422:05PRNUS10x Genomics Reports Fourth Quarter and Full Year 2023..
13/2/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202422:05PRNUS10x Genomics Expands Leadership in Single Cell Analysis with..
05/2/202422:05PRNUS10x Genomics to Showcase New Cutting-Edge Technologies and..
24/1/202422:05PRNUS10x Genomics to Report Fourth Quarter and Full Year 2023..
18/1/202422:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/1/202400:08EDGAR2Form 144 - Report of proposed sale of securities
16/1/202422:07EDGAR2Form 8-K - Current report
08/1/202415:00EDGAR2Form 8-K - Current report
08/1/202415:00PRNUS10x Genomics Announces Preliminary Fourth Quarter and Full..
29/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202322:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202322:05PRNUS10x Genomics to Present at the 42nd Annual J.P. Morgan..
20/12/202322:05PRNUS10x Genomics Launches Xenium Catalyst Network
19/12/202315:00PRNUSIntegrative Study Conducted by 10x Genomics Combines Single..
18/12/202323:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202323:09EDGAR2Form 144 - Report of proposed sale of securities
13/12/202322:26PRNUSHigh Sensitivity and Specificity of the Xenium Platform from..
07/12/202315:00PRNUS10x Genomics and NIH CARD to Create Comprehensive Single..
28/11/202300:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 19,68 Min: 19,20 Max: 20,01
Chiusura: 19,77

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network